Amphastar Pharma Cash Flow - Quarterly (NASDAQ:AMPH)

Add to My Stocks
$19.91 $0.12 (0.61%) AMPH stock closing price Mar 16, 2018 (Closing)

The financial analysis of AMPH requires an investor to check the cash flows for Amphastar Pharma. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Amphastar Pharma profits and Amphastar Pharma debt. Amphastar Pharma saw a cash impact of $-17.51M from the buyback of AMPH shares. The cash flow statement helps in the Amphastar Pharma stock analysis by providing more information for evaluating changes in assets, liabilities and equities. The cash from operating activities for Amphastar Pharma is $ 2017 Q3, which saw an increase from previous quarter.

View and download details of Amphastar Pharma cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow11.51M7.66M3.82M14.56M10.76M7.04M3.42M13.25M9.97M
Net Increase (Decrease) in Assets Liabilities4.26M10.24M15.86M--12.13M-2.18M3.9M-5.13M1.72M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net10.62M6.2M1.81M13.16M12.65M9.01M4.1M5.35M6.01M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-24.98M-14.69M-7.26M-21.38M-16.04M-9.34M-3.94M-15.99M-11.87M
Acquisition Disposition of Subsidiaires----12.46M-12.46M-4.76M-4.76M--
Increase (Decrease) in Investments-1.99M-0.2M-0.34M-0.52M-0.85M----
Other Cash Inflow (Outflow) from Investment Activities-1.65M-0.76M1.52M-5.13M-3.02M-3.32M-0.71M-0.92M-0.59M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares-17.51M-9.9M-10.37M10.73M8.17M-5.26M-5.7M4.33M4.99M
Issuance (Repayment) of Debt Securities10.6M8.5M-1.34M-4.45M---1.33M-2.2M2.81M
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities---------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---0.17M--0.04M-0.17M-0.21M2.25M-
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year66.07M67.82M53.58M50.21M53.73M53.75M---
Cash & Equivalents at Year End66.92M82.54M76.76M72.35M66.59M66.66M63.33M66.07M70.68M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Amphastar Pharma stock price history provides insight into historical stock price fluctuations, and Amphastar Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Amphastar Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Amphastar Pharma stock price movement.
  • Amphastar Pharma increased its cash from operating activities to $29.44M till 2017 Q3. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Amphastar Pharma used $-28.62M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-6.91M for Amphastar Pharma.

Key Financial Ratios For Amphastar Pharma Cash Flow

Quarterly Cash Flow Statements For Amphastar Pharmaceuticals Inc Peers

AxoGen cash flow, Halozyme Therapeutics cash flow, Sanofi cash flow, Teligent cash flow